TORONTO, June 13, 2011 /PRNewswire/ --
- Medworxx UMS Patient Flow Solution is Optimized to Support NICE Guidance and Pathways
Medworxx Inc. (TSXV: MWX), an emerging leader in clinical patient flow solutions, announces the alignment of its health information technology solution to guidance set by the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom. For more than 300 international hospitals, Medworxx ensures the daily use of guidance-based patient flow assessments.
"Like the NHS and NICE, we rely on an evidence-base for the clinical cornerstones of our system - and this depth in clinical best practices makes our solutions easily adaptable to international guidance. We are proud that our patient flow solution is in line with the guidance most depended upon in the UK," says Wendy McLaughlin, RN, Vice President, Clinical Services for Medworxx.
Clinical alignment with guidance and pathways is mission-critical to the company's internationally-offered solution which assesses barriers and delays in daily patient flow against clinical criteria.
"In hospitals in England and Wales, such as Royal Liverpool and Broadgreen University Hospitals, compliance with NICE guidance is essential to avoid clinically unnecessary admissions to hospital, to reduce length of stay in-hospital, and to transition to home-based programmes. Applying the Medworxx criteria in accordance with NICE, alongside our other patient journey and commissioning tools, enables us to assess appropriate levels of care and patients' readiness for discharge - and ultimately to inform Trusts and Commissioners of the major opportunities and solid actions they can take in this direction," said Karen Dunwell, Chief Executive, ModelAdvice DC Consulting Ltd UK. "This will lead to the development of a vertically integrated health system with the clinical quality and affordability required by our NHS environment."
NICE is engaged in developing and defining pathways, standards of healthcare and a quality and outcomes framework for the United Kingdom, in addition to making recommendations to the National Health Service (NHS) on new and existing medicines, treatments and procedures. Medworxx incorporates review of NICE guidelines along with other international sources into building the evidence-based clinical criteria at the heart of its patient flow solutions.
The Medworxx Community of Care engages more than 500,000 people at over 300 hospitals across Canada, Unites States and United Kingdom to manage daily challenges in clinical patient flow, and requirements in compliance and education. Founded in 2004, Medworxx Inc. is based in Toronto, Ontario, Canada and serves international markets. The company is publicly traded on the TSX Venture Exchange (TSXV: MWX). For more information, visit http://www.medworxx.com.
The statements made in this press release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the company's expectations and projections. The TSX Venture Exchange has not reviewed this press release and neither approved nor disapproved the information contained in this press release.
For further information:
Julia Zarb, PhD
SVP Marketing & Strategy, Medworxx Inc.
Suite 700, 121 Richmond St West, Toronto, Canada M5H 2K1
T: +1-800-321-1591 | T: +1-416-642-1278 x322 | M: +1-416-418-3641
Jzarb@medworxx.com | http://www.Medworxx.com
SOURCE Medworxx Inc.